Category: 445490-78-8

On July 31, 2006, Raboisson, Pierre; Manthey, Carl L.; Chaikin, Margery; Lattanze, Jennifer; Crysler, Carl; Leonard, Kristi; Pan, Wenxi; Tomczuk, Bruce E.; Marugan, Juan Jose published an article.Application of 445490-78-8 The title of the article was Novel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin. And the article contained the following:

Pyridopyridineethoxy- and pyridopyridinepropyl-substituted indolepropanoic acids, a pyridineaminopropoxydihydroindoleacetic acid, and a substituted oxopyrrolopyrimidinepropanoic acid are prepared as potential selective dual αvβ3 and αvβ5 integrin receptor antagonists with decreased binding to human serum albumin (HSA). Ammonium tetrahydronaphthyridinylethoxyindolepropanoate I•NH3 is the most effective of the compounds prepared, with subnanomolar affinity for both αvβ3 and αvβ5 (IC50 = 0.29 and 0.16 nM, resp.), low HSA protein binding (40% bound, Kd = 1.1 ± 0.4 × 103 μM), and improved in vitro stability toward human and mouse microsomes (99.9% and 98.7% remaining after 10 min) over previously prepared integrin receptor antagonists. The selectivities of I•NH3 toward α5β1 and IIbIIIa integrins is comparable to those of the initial lead integrin receptor antagonists. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Application of 445490-78-8

The Article related to pyridopyridineethoxy indolepropanoic acid preparation integrin receptor antagonist, pyridopyridinepropyl indolepropanoic acid preparation integrin receptor antagonist, oxopyrrolopyrimidinepropanoic acid pyridopyridineethoxy preparation integrin receptor antagonist and other aspects.Application of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On March 7, 2002, Ish, Kumar Khanna; Yi, Yu; Balekudru, Devadas; Hwang-Fun, Lu; Nizal, S. Chandrakumar published a patent.Product Details of 445490-78-8 The title of the patent was Compounds containing a pyridinylaminopropoxybicyclic ring system useful as αvβ3 antagonists. And the patent contained the following:

Title compounds were prepared for use as selective inhibitors or antagonists of the αvβ3 and/or αvβ5 integrin. Thus, the benzoxazepine I was prepared by treating 4-benzyloxysalicylaldehyde with BrCMe2CO2CH2Ph and H2NCH2CO2CMe3, debenzylating, cyclizing, reaction with 2-(3-hydroxypropylamino)pyridine 1-oxide, reduction of the N-oxide, and ester hydrolysis. The compounds showed activity in several vitronectin receptor assays. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Product Details of 445490-78-8

The Article related to pyridinylaminopropoxy bicyclic compound preparation vitronectin receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Other 7-Membered Rings and other aspects.Product Details of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On April 2, 2015, Fukunaga, Hirofumi; Dozono, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Nagano, Akio published a patent.Synthetic Route of 445490-78-8 The title of the patent was Preparation of nitrogen-containing compounds or their metal complexes as therapeutic and radiodiagnostic agents for integrin-related disorders. And the patent contained the following:

The nitrogen-containing compounds, their salts, or their metal complexes are represented by formula I [A1 = chelate group; R1, R2 = H, (un)substituted C1-6 alkyl, amino protective group; Z1-Z5 = N, CR3; R3 = H, halo, (un)substituted C1-6 alkyl, (un)substituted pyridinyl-containing sulfonyl group; L1 = [NR13(CR14CR15O)qCR16CO]r; L2, L3 = (un)substituted C1-6 alkylene; R13 = H, (un)substituted C1-6 alkyl, amino protective group; R14, R15 = H, (un)substituted C1-6 alkyl; R16 = H, (un)substituted C1-6 alkyl, aromatic or heterocycle amide-containing group]. Thus, reacting tetrahydronaphthyridine terminal-containing cysteic acid (preparation given) with tri-tert-Bu 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate, and deprotecting tert-Bu groups with aqueous LiOH, gave tetraazacyclododecane ring-containing tricarboxylic acid. The tetraazacyclododecane ring-containing tricarboxylic acid can give complexes with radioactive metals showing high concentration and retention in the cancer cells. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Synthetic Route of 445490-78-8

The Article related to heterocycle metal complex preparation integrin disorder cancer radiodiagnostic, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Synthetic Route of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On May 17, 2018, Devasthale, Pratik; Moore, Fang; Zhao, Guohua; Pieniazek, Susan Nicole; Selvakumar, Kumaravel; Dhanusu, Suresh; Panda, Manoranjan; Marcin, Lawrence R. published a patent.Application In Synthesis of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate The title of the patent was Cyclobutane- and azetidine-containing mono- and spirocyclic compounds as alpha v integrin inhibitors and their preparation. And the patent contained the following:

The invention provides compounds of formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathol. fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions Compounds of formula I wherein A is a covalent bond, CO, O, C1-3 alkoxy, CONH and derivatives, etc.; E is cyclobutylene, azetidinylene, and [3.3.0]bicyclic moiety; X is C1-5 alkylene and (un)substituted phenylene; Y is a bond, CO, O, NH and derivatives, etc.; R1 is (un)substituted imidazolylamino, (un)substituted pyridinylamino, (un)substituted benzimidazolylamino, guanidino, etc.; R3 is H, C1-6 alkyl, C3-10 cycloalkyl, C6-10 aryl, etc.; R4 is H, halo, C1-6 alkyl, C3-10 carbocyclyl,e tc.; R4a is H, halo and C1-6 alkyl, R5 is H, C1-6 alkyl, Ph, benzyl, etc.; Z is N and CH; and pharmaceutically acceptable salts thereof, are claimed. Example compound II•TFA was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their αVβ6 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 420 nM. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Application In Synthesis of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

The Article related to cyclobutane azetidine containing spirocycle preparation alpha v integrin inhibitor, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Application In Synthesis of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On May 16, 2005, Leonard, Kristi; Pan, Wenxi; Anaclerio, Beth; Gushue, Joan M.; Guo, Zihong; DesJarlais, Renee L.; Chaikin, Marge A.; Lattanze, Jennifer; Crysler, Carl; Manthey, Carl L.; Tomczuk, Bruce E.; Marugan, Juan Jose published an article.SDS of cas: 445490-78-8 The title of the article was Non-peptidic αvβ3 antagonists containing indol-1-ylpropionic acids. And the article contained the following:

The synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ3 are described. Indol-1-ylpropionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).SDS of cas: 445490-78-8

The Article related to indolylpropionic acid preparation vitronectin receptor antagonist, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.SDS of cas: 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On October 12, 2006, Roboisson, Pierre; Marugan Sanchez, Juan Jose published a patent.COA of Formula: C15H22N2O3 The title of the patent was Preparation of 4-substituted indoles for use as integrin antagonists. And the patent contained the following:

4-Substituted indoles I, wherein R is Ph or 3-pyridyl; X-Y is -CH2-O-, -CH2-NH-, or -CH2-CH2-; W can be II or III wherein R1 is hydrogen, alkyl, haloalkyl or halogen; R2 and R3 are independently hydrogen, halogen or alkyl; R4 and R5 are independently hydrogen, halogen, alkyl, alkoxy or aryl; R6 is hydrogen are prepared . Thus, IV was prepared and tested integrin antagonists, however, no biol. data was provided. Further, I may be used in the treatment of pathol. conditions mediated by avss3 and avss5 integrins, including but not limited to tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).COA of Formula: C15H22N2O3

The Article related to integrin antagonist human indole, indole preparation integrin antagonist, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.COA of Formula: C15H22N2O3

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On August 8, 2002, Lu, Tianbao; Lafrance, Louis Vincent; Markotan, Thomas P.; Marugan, Juan Jose; Marder, Victor J.; U’Prichard, David C.; Anaclerio, Beth M.; Guo, Zihong; Pan, Wenxi; Leonard, Kristi A. published a patent.Computed Properties of 445490-78-8 The title of the patent was Preparation of indoles and their use as αvβ3 and αvβ5 integrin antagonists. And the patent contained the following:

Title compounds I [R1-R5 = H, halo, alkyl, etc.; R6-R9 = H, alkyl, hydroxyalkyl, etc.; R10-R13 = H, OH, alkyl, etc.; R14 = H, or a functionality that acts as a prodrug; X = O, S, CH2, etc.; a, k, v = 0, 1; i, j, m, n = 0-4], their pharmaceutically acceptable salts, prodrugs and formulations were prepared For example, hydrogenation of acrylic ester II, prepared from 7-[2-[1-(2-Methoxycarbonyl-1-(pyridin-3-yl)vinyl)-1H-indol-5-yloxy]ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-Bu ester and pyridin-3-ylpropynoic acid Me ester, followed by BOC deprotection, and ester hydrolysis provided claimed indole III. Indole III inhibited human αvβ3-vitronectin interaction at an IC50 of 0.24 nM, studies for an addnl. 6 examples are provided, ranging in values from 670 to 0.24 nM. Compounds I may be used in treatment of pathol. conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, inflammation, rheumatoid arthritis, etc.. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Computed Properties of 445490-78-8

The Article related to preparation indole integrin antagonist antitumor antiinflammatory antirheumatic, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Computed Properties of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On November 7, 2002, Sanchez, Juan Jose Marugan; Marder, Victor J.; U’prichard, David C. published a patent.Quality Control of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate The title of the patent was Substituted benzofurans and benzothiophenes of use as integrin antagonists. And the patent contained the following:

Title compounds I [Y = O, S; X = O, S, CH2, NH; W = N heterocyclic, amino; Z = CR5R6(CH2)i(CR7R8)k(CH2)jCO2R9; R1-R4 = H, alkyl, haloalkyl, aryl, aralkyl; R5-R8 = H, OH, (un)substituted alkyl, alkoxy, cycloalkyl, aryl, heterocyclic; R5R7 = alkylene; R9 = H, alkyl, haloalkyl, aryl, aralkyl, aminoalkyl, alkoxyalkoxyalkyl, alkoxycarbonyloxyethyl; R10-R13 = H, (un)substituted alkyl, aryl; R10R11 = alkylene; i, j, m, n = 0-4; k = 0, 1] were prepared The compounds may be used in the treatment of pathol. conditions mediated by αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. Thus, the benzothiophene II was prepared from tert.-Bu 7-ethoxycarbonylmethyl-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylate and Et 3-(6-hydroxybenzo[b]thiophen-3-yl)propionate and had IC50 for inhibition of αvβ5-vitronectin in vitro of 8 nM. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Quality Control of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

The Article related to benzothiophenepropionate preparation vitronectin inhibitor, benzofuranpropionate preparation vitronectin inhibitor, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Quality Control of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On April 20, 2011, Kroth, Heiko; Froestl, Wolfgang; Pfeifer, Andrea; Muhs, Andreas published a patent.Product Details of 445490-78-8 The title of the patent was Preparation of 2,6-diaminopyridine compounds for treating diseases associated with amyloid proteins, especially ocular diseases. And the patent contained the following:

The invention is related to the preparation of diaminopyridines I [the pyridine rings A, B, and C are independently (un)substituted by ≥1 substituents selected from alkyl, NH2 and derivatives, CN, NO2, CO2H, etc.; R1, R2 = independently H, (un)substituted 5-10 membered heteroaryl, alkynyl, cycloalkyl, etc.; L1, L2 = independently NR3CR4R5(CR6R7)p, (CR8R9)qCR10R11NR12; R3, R12 = independently H, CH(:NOH) and derivatives, CONH2 and derivatives, (un)substituted 5-10 membered heterocycloalkylalkyl, etc.; R4-11 = independently SO2NH2 and derivatives, aminocarbonylalkyl, halo, OCONH2 and derivatives, etc.; p = 1-2; q = 0-2] and their pharmaceutical acceptable salts that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The invention is also related to the use of I in the treatment of ocular diseases associated with pathol. abnormalities/changes in the tissues of the visual system. Thus, II was prepared by a multi-step synthesis from 2-bromo-6-methylpyridine and inhibited the aggregation of amyloid beta 1-42 peptide in a thioflavin T spectrofluorescence assay (IC50 = 12.9 mM). The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Product Details of 445490-78-8

The Article related to pyridinediamine preparation amyloid beta protein abnormality ocular disease, glaucoma intraocular pressure amyloidosis naphthyridinylalkyl pyridinylalkyl pyridinediamine preparation and other aspects.Product Details of 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem

On April 21, 2011, Kroth, Heiko; Froestl, Wolfgang; Pfeifer, Andrea; Muhs, Andreas published a patent.SDS of cas: 445490-78-8 The title of the patent was Preparation of 2,6-diaminopyridine compounds for treating diseases associated with amyloid or amyloid-like proteins, especially ocular diseases. And the patent contained the following:

The invention is related to the preparation of diaminopyridines I [the pyridine rings A, B, and C are independently (un)substituted by ≥1 substituents selected from alkyl, NH2 and derivatives, CN, NO2, CO2H, etc.; R1, R2 = independently H, (un)substituted 5-10 membered heteroaryl, alkynyl, cycloalkyl, etc.; L1, L2 = independently NR3CR4R5(CR6R7)p, (CR8R9)qCR10R11NR12; R3, R12 = independently H, CH(:NOH) and derivatives, CONH2 and derivatives, (un)substituted 5-10 membered heterocycloalkylalkyl, etc.; R4-11 = independently SO2NH2 and derivatives, aminocarbonylalkyl, halo, OCONH2 and derivatives, etc.; p = 1-2; q = 0-2] and their pharmaceutical acceptable salts that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The invention is also related to the use of I in the treatment of ocular diseases associated with pathol. abnormalities/changes in the tissues of the visual system. Thus, II was prepared by a multi-step synthesis from 2-bromo-6-methylpyridine and inhibited the aggregation of amyloid beta 1-42 peptide in a thioflavin T spectrofluorescence assay (IC50 = 12.9 μM). The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).SDS of cas: 445490-78-8

The Article related to pyridinediamine preparation amyloid beta protein abnormality ocular disease, glaucoma intraocular pressure amyloidosis naphthyridinylalkyl pyridinylalkyl pyridinediamine preparation and other aspects.SDS of cas: 445490-78-8

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem